| 摘要 |
The present invention relates to a novel approach to identifying and managing cardiac arrhythmogenic risks associated with prolongation and/or dispersion of ventricular repolarization. The arrhythmogenic risks may be, for example, congenital, acquired, or drug induced, such as drug- induced Long QT Syndrome. As described herein, arrhythmogenic risks encompass ectopic beats, sustained and/or non-sustained ventricular tachycardia, e.g., Torsades de Pointes and ventricular fibrillation, and torsadogenic risks and QT prolongation risks. Accordingly, the present invention also relates to a novel approach to identifying and managing torsadogenic risk, for example, congenital, acquired, and drug induced, including but not limited to the torsadogenic risk created by antiarrhythmic drugs and other classes of drugs. The present invention also relates to a novel approach to identifying and managing QT prolongation risk, for example, as it relates to congenital, acquired, and drug induced risk, including but not limited to the QT prolongation risk created by CNS active compounds, antihistamines, antimicrobi- als, and gastro-intestinal drugs, and other drug classes. |
